Redeye strengthens its confidence in the Episurf equity story, following the Capital Markets Day held last week. We have revised our long-term sales and are now closer aligned with the management’s targets. However, we want to see further clinical evidence and the first mark on top-line before we feel entitled to raise our estimates even further. Nonetheless, our revised estimates have a positive impact on all our fair values.